Patents by Inventor Yevgeniy S. Belousov
Yevgeniy S. Belousov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10975423Abstract: Methods, primers and probes are provided for the isothermal amplification and detection, without denaturation, of double stranded nucleic acid targets for polymerase strand displacement amplification (“iSDA”). The methods and compositions disclosed are highly specific for nucleic acid targets with high sensitivity, specificity and speed that allow detection of clinical relevant target levels. The methods and compositions can easily be used to amplify or detect nucleic acid targets in biological samples.Type: GrantFiled: October 23, 2019Date of Patent: April 13, 2021Assignee: ELITECHGROUP, INC.Inventors: Yevgeniy S. Belousov, Eugeny A. Lukhtanov, Noah Scarr
-
Patent number: 10590474Abstract: Methods, primers and probes are provided for the isothermal amplification and detection, without denaturation, of double stranded nucleic acid targets for polymerase strand displacement amplification (“iSDA”). The methods and compositions disclosed are highly specific for nucleic acid targets with high sensitivity, specificity and speed that allow detection of clinical relevant target levels. The methods and compositions can easily be used to amplify or detect nucleic acid targets in biological samples.Type: GrantFiled: December 20, 2017Date of Patent: March 17, 2020Assignee: ELITECHGROUP B.V.Inventors: Yevgeniy S. Belousov, Boris Alabeyev, Noah Scarr
-
Publication number: 20200040387Abstract: Methods, primers and probes are provided for the isothermal amplification and detection, without denaturation, of double stranded nucleic acid targets for polymerase strand displacement amplification (“iSDA”). The methods and compositions disclosed are highly specific for nucleic acid targets with high sensitivity, specificity and speed that allow detection of clinical relevant target levels. The methods and compositions can easily be used to amplify or detect nucleic acid targets in biological samples.Type: ApplicationFiled: October 23, 2019Publication date: February 6, 2020Applicant: ELITechGroup, Inc.Inventors: Yevgeniy S. Belousov, Eugeny A. Lukhtanov, Noah Scarr
-
Patent number: 10266903Abstract: Primers and probes specific to the genes encoding extended spectrum beta-lactamase that involves CTX-M groups 1 and 9 that cause extended beta-lactamase resistance in bacteria are described herein, with methods and kits for using these primers and probes to detect CTX-M groups 1 and 9 nucleic acids. In the methods described, nucleic acids present in a clinical or test sample obtained from a biological sample or tissue suspected of containing the CTX-M groups 1 and 9 gene are amplified and corresponding sequences for CTX-M groups 1 and 9 are detected. The amplified nucleic acid can be detected by a variety of state of the art methods, including fluorescence resonance energy transfer (FRET), radiolabels, enzyme labels, and the like.Type: GrantFiled: December 3, 2015Date of Patent: April 23, 2019Assignee: ELITECHGROUP, INC.Inventors: Irina A. Afonina, Yevgeniy S. Belousov
-
Patent number: 9988670Abstract: Primers and probes specific to genes encoding carbapenem-resistant Enterobacteriaceae (CREs) that include KPC (Klebsiella pneumoniae carbapenemase), NDM-1 (New Delhi Metallo-beta-lactamase), VIM (Verona Integron-Mediated Metallo-?-lactamase), IMP-type carbapenemase and OXA 48 (oxacillinase), that cause resistance in Enterobacteriaceae bacteria, are described herein, with methods and kits for using these primers and probes to detect target nucleic acids. In the methods described, nucleic acids present in a clinical or test sample obtained from a biological sample or tissue suspected of containing the the NDM1, KPC, IMP, VIM and OXA genes are amplified and corresponding sequences for the NDM1, KPC, IMP, VIM and OXA genes are detected. The amplified nucleic acid can be detected by a variety of state of the art methods, including fluorescence resonance energy transfer (FRET), radiolabels, enzyme labels, and the like.Type: GrantFiled: December 10, 2015Date of Patent: June 5, 2018Assignee: ELITECHGROUP B.V.Inventors: Irina A. Afonina, Yevgeniy S. Belousov
-
Publication number: 20180127815Abstract: Methods, primers and probes are provided for the isothermal amplification and detection, without denaturation, of double stranded nucleic acid targets for polymerase strand displacement amplification (“iSDA”). The methods and compositions disclosed are highly specific for nucleic acid targets with high sensitivity, specificity and speed that allow detection of clinical relevant target levels. The methods and compositions can easily be used to amplify or detect nucleic acid targets in biological samples.Type: ApplicationFiled: December 20, 2017Publication date: May 10, 2018Applicant: ElitechGroup B.V.Inventors: Yevgeniy S. Belousov, Boris Alabeyev, Noah Scarr
-
Patent number: 9932643Abstract: The present methods pertain to amplifying and/or detecting Staphylococcus aureus (“SA”) and methicillin-resistant Staphylococcus aureus (“MRSA”) nucleic acids based on a combined detection of ldh1 as a SA marker and mecA as a MRSA marker. In certain embodiments the methods also pertain to amplifying and/or detecting one or more SCCmec integration sites or bridge regions. Primers and probes are suitable to be used in the present methods to detect SA and MRSA simultaneously in a single reaction or in separate reactions. The amplified nucleic acid can be detected by a variety of state of the art methods, including fluorescence resonance energy transfer (“FRET”), radiolabels, enzyme labels, and the like.Type: GrantFiled: March 9, 2017Date of Patent: April 3, 2018Assignee: ELITECHGROUP B.V.Inventors: Irina A. Afonina, Yevgeniy S. Belousov, Walt Mahoney
-
Publication number: 20170183717Abstract: The present methods pertain to amplifying and/or detecting Staphylococcus aureus (“SA”) and methicillin-resistant Staphylococcus aureus (“MRSA”) nucleic acids based on a combined detection of ldh1 as a SA marker and mecA as a MRSA marker. In certain embodiments the methods also pertain to amplifying and/or detecting one or more SCCmec integration sites or bridge regions. Primers and probes are suitable to be used in the present methods to detect SA and MRSA simultaneously in a single reaction or in separate reactions. The amplified nucleic acid can be detected by a variety of state of the art methods, including fluorescence resonance energy transfer (“FRET”), radiolabels, enzyme labels, and the like.Type: ApplicationFiled: March 9, 2017Publication date: June 29, 2017Inventors: Irina A. Afonina, Yevgeniy S. Belousov, Walt Mahoney
-
Patent number: 9677142Abstract: The present methods pertain to amplifying and/or detecting Staphylococcus aureus (“SA”) and methicillin-resistant Staphylococcus aureus (“MRSA”) nucleic acids based on a combined detection of ldh1 as a SA marker and mecA as a MRSA marker. In certain embodiments the methods also pertain to amplifying and/or detecting one or more SCCmec integration sites or bridge regions. Primers and probes are suitable to be used in the present methods to detect SA and MRSA simultaneously in a single reaction or in separate reactions. The amplified nucleic acid can be detected by a variety of state of the art methods, including fluorescence resonance energy transfer (“FRET”), radiolabels, enzyme labels, and the like.Type: GrantFiled: May 24, 2012Date of Patent: June 13, 2017Assignee: ELITECHGROUP B.V.Inventors: Irina A. Afonina, Yevgeniy S. Belousov, Walt Mahoney
-
Publication number: 20160168628Abstract: Primers and probes specific to the genes encoding extended spectrum beta-lactamase that involves CTX-M groups 1 and 9 that cause extended beta-lactamase resistance in bacteria are described herein, with methods and kits for using these primers and probes to detect CTX-M groups 1 and 9 nucleic acids. In the methods described, nucleic acids present in a clinical or test sample obtained from a biological sample or tissue suspected of containing the CTX-M groups 1 and 9 gene are amplified and corresponding sequences for CTX-M groups 1 and 9 are detected. The amplified nucleic acid can be detected by a variety of state of the art methods, including fluorescence resonance energy transfer (FRET), radiolabels, enzyme labels, and the like.Type: ApplicationFiled: December 3, 2015Publication date: June 16, 2016Inventors: Irina A. Afonina, Yevgeniy S. Belousov
-
Publication number: 20160168625Abstract: Primers and probes specific to genes encoding carbapenem-resistant Enterobacteriaceae (CREs) that include KPC (Klebsiella pneumoniae carbapenemase), NDM-1 (New Delhi Metallo-beta-lactamase), VIM (Verona Integron-Mediated Metallo-?-lactamase), IMP-type carbapenemase and OXA 48 (oxacillinase), that cause resistance in Enterobacteriaceae bacteria, are described herein, with methods and kits for using these primers and probes to detect target nucleic acids. In the methods described, nucleic acids present in a clinical or test sample obtained from a biological sample or tissue suspected of containing the the NDM1, KPC, IMP, VIM and OXA genes are amplified and corresponding sequences for the NDM1, KPC, IMP, VIM and OXA genes are detected. The amplified nucleic acid can be detected by a variety of state of the art methods, including fluorescence resonance energy transfer (FRET), radiolabels, enzyme labels, and the like.Type: ApplicationFiled: December 10, 2015Publication date: June 16, 2016Inventors: Irina A. Afonina, Yevgeniy S. Belousov
-
Publication number: 20150275274Abstract: The present methods pertain to amplifying and/or detecting Staphylococcus aureus (“SA”) and methicillin-resistant Staphylococcus aureus (“MRSA”) nucleic acids based on a combined detection of ldh1 as a SA marker and mecA as a MRSA marker. In certain embodiments the methods also pertain to amplifying and/or detecting one or more SCCmec integration sites or bridge regions. Primers and probes are suitable to be used in the present methods to detect SA and MRSA simultaneously in a single reaction or in separate reactions. The amplified nucleic acid can be detected by a variety of state of the art methods, including fluorescence resonance energy transfer (“FRET”), radiolabels, enzyme labels, and the like.Type: ApplicationFiled: May 24, 2012Publication date: October 1, 2015Inventors: Irina A. Afonina, Yevgeniy S. Belousov, Walt Mahoney
-
Publication number: 20140255928Abstract: Methods, primers and probes are provided for the isothermal amplification and detection, without denaturation, of double stranded nucleic acid targets for polymerase strand displacement amplification (“iSDA”). The methods and compositions disclosed are highly specific for nucleic acid targets with high sensitivity, specificity and speed that allow detection of clinical relevant target levels. The methods and compositions can easily be used to amplify or detect nucleic acid targets in biological samples.Type: ApplicationFiled: March 10, 2014Publication date: September 11, 2014Applicant: Elitech Holding B.V.Inventors: Yevgeniy S. Belousov, Boris Alabeyev, Noah Scarr
-
Patent number: 7485442Abstract: Oligonucleotide probes/conjugates are provided along with method for their use in assays to monitor amplification wherein the signal produced does not rely on 5? nuclease digestion.Type: GrantFiled: June 19, 2006Date of Patent: February 3, 2009Assignee: Epoch Biosciences, Inc.Inventors: Irina A. Afonina, Yevgeniy S. Belousov, Robert O. Dempcy, Igor V. Kutyavin, Sergey G. Lokhov, Eugeny A. Lukhtanov
-
Patent number: 7205105Abstract: Oligonucleotide probes/conjugates are provided along with method for their use in assays to monitor amplification wherein the signal produced does not rely on 5? nuclease digestion.Type: GrantFiled: June 6, 2002Date of Patent: April 17, 2007Assignee: Epoch Biosciences, Inc.Inventors: Irina A. Afonina, Yevgeniy S. Belousov, Robert O. Dempcy, Igor V. Kutyavin, Sergey G. Lokhov, Eugeny A. Lukhtanov
-
Patent number: 6962991Abstract: The present invention provides a nucleoside comprising a pyrazolopyrimidine base and a process for producing the same. In particular, the processes of the present invention comprises using a halogenated pyrazolopyrimidine base and removing the halogen after the base is coupled to a sugar moiety. The presence of the halogen on the nucleoside base allows facile and economical production of a large quantity of nucleosides.Type: GrantFiled: September 12, 2001Date of Patent: November 8, 2005Assignee: Epoch Biosciences, Inc.Inventors: Robert O. Dempcy, A. David Adams, Michael W. Reed, Yevgeniy S. Belousov
-
Publication number: 20040191824Abstract: The present invention provides a nucleoside comprising a pyrazolopyrimidine base and a process for producing the same. In particular, the processes of the present invention comprises using a halogenated pyrazolopyrimidine base and removing the halogen after the base is coupled to a sugar moiety. The presence of the halogen on the nucleoside base allows facile and economical production of a large quantity of nucleosides.Type: ApplicationFiled: April 1, 2004Publication date: September 30, 2004Applicant: Epoch Biosciences, Inc.Inventors: Robert O. Dempcy, A. David Adams, Michael W. Reed, Yevgeniy S. Belousov
-
Publication number: 20030175728Abstract: Oligonucleotide probes/conjugates are provided along with method for their use in assays to monitor amplification wherein the signal produced does not rely on 5′ nuclease digestion.Type: ApplicationFiled: June 6, 2002Publication date: September 18, 2003Applicant: Epoch Biosciences, Inc.Inventors: Yevgeniy S. Belousov, Irina A. Afonina